PRESS RELEASES

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary ERYTECH Announces Collaboration with Queen’s University to Advance its Product Candidate for Rare Metabolic Disorders
LYON, France --(BUSINESS WIRE)--Jul. 12, 2017-- Regulatory News: ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) (Euronext Paris - ERYP), a French clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases, today announced that it has entered into
View HTML
Toggle Summary ERYTECH Announces Commencement of Trading of ADSs on Nasdaq and Full Exercise of Underwriters’ Option, Bringing Gross Proceeds of Global Offering to $144 Million
Base deal of $125 million in gross proceeds from specified categories of specialized investors closed on November 14, 2017 . Announced full exercise of underwriters’ option to purchase additional American Depositary Shares (ADSs) and Ordinary Shares, with closing expected to take place on or about
View HTML
Toggle Summary ERYTECH Announces Commencement of Trading of ADSs on Nasdaq and Full Exercise of Underwriters’ Option, Bringing Gross Proceeds of Global Offering to $144 Million
Base deal of $125 million in gross proceeds from specified categories of specialized investors closed on November 14, 2017 . Announced full exercise of underwriters’ option to purchase additional American Depositary Shares (ADSs) and Ordinary Shares, with closing expected to take place on or about
View HTML
Toggle Summary ERYTECH Announces Launch of Investigator-Initiated Phase 2 Study of eryaspase (GRASPA®) for ALL
LYON, France --(BUSINESS WIRE)--Apr. 4, 2017-- Regulatory News : ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) a French clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the launch of an
View HTML
Toggle Summary ERYTECH Announces Launch of Proposed Global Offering and NASDAQ Listing
LYON, France --(BUSINESS WIRE)--Nov. 6, 2017-- Regulatory News : ERYTECH Pharma (Euronext Paris: ERYP) (ADR: EYRYY) (“ERYTECH” or the "Company") (Paris:ERYP) (ADR:EYRYY) , a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside
View HTML
Toggle Summary ERYTECH Announces Launch of Proposed Global Offering and NASDAQ Listing
LYON, France --(BUSINESS WIRE)--Nov. 6, 2017-- Regulatory News : ERYTECH Pharma (Euronext Paris: ERYP) (ADR: EYRYY) (“ERYTECH” or the "Company") (Paris:ERYP) (ADR:EYRYY) , a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside
View HTML
Toggle Summary ERYTECH Announces Positive Full Results from Phase 2b Study of Eryaspase in Combination with Chemotherapy for Treatment of Metastatic Pancreatic Cancer in Second-Line
Full data demonstrates statistically significant improvement in both overall survival and progression-free survival for eryaspase as second-line treatment of metastatic pancreatic cancer Data to be presented at the European Society for Medical Oncology (ESMO) Annual Meeting in Madrid ( September
View HTML
Toggle Summary ERYTECH Announces Positive Full Results from Phase 2b Study of Eryaspase in Combination with Chemotherapy for Treatment of Metastatic Pancreatic Cancer in Second-Line
Full data demonstrates statistically significant improvement in both overall survival and progression-free survival for eryaspase as second-line treatment of metastatic pancreatic cancer Data to be presented at the European Society for Medical Oncology (ESMO) Annual Meeting in Madrid ( September
View HTML
Toggle Summary ERYTECH Announces Pricing of Global Offering and Approval to List on Nasdaq Global Select Market
LYON, France --(BUSINESS WIRE)--Nov. 10, 2017-- Regulatory News : NOT FOR DISTRIBUTION IN AUSTRALIA , CANADA AND JAPAN ERYTECH Pharma (Paris:ERYP) ("ERYTECH" or the "Company"), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances
View HTML
Toggle Summary ERYTECH Announces Pricing of Global Offering and Approval to List on Nasdaq Global Select Market
LYON, France --(BUSINESS WIRE)--Nov. 10, 2017-- Regulatory News : NOT FOR DISTRIBUTION IN AUSTRALIA , CANADA AND JAPAN ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) ("ERYTECH" or the "Company"), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug
View HTML
Top